Literature DB >> 2618522

In vitro activity of amoxycillin plus clavulanic acid and ticarcillin plus clavulanic acid compared with that of other antibiotics against anaerobic bacteria.

D Pierard, A De Meyer, P Rosseel, Y Glupczynski, M J Struelens, M Delmee, S R Pattyn, G Verschraegen, P Melin, S Lauwers.   

Abstract

The activity of amoxycillin/clavulanic acid (Augmentin) and ticarcillin/clavulanic acid (Timentin) was tested against 303 unselected clinical anaerobic isolates recently collected in seven Belgian university hospitals and compared with that of 11 other antimicrobial agents. Bacteroides spp. accounted for 52.1% of the isolates, Clostridium spp. for 23.4%, anaerobic cocci for 15.5%, nonsporeforming gram-positive bacilli for 4.6% and Fusobacterium spp. for 3.3%. Ticarcillin/clavulanic acid (fixed clavulanic acid concentration of 2 mg/l) was the most active drug with an overall susceptibility rate of 99.7%. Amoxycillin/clavulanic acid (fixed ratio of 2:1) and chloramphenicol inhibited 97.4% of the isolates, metronidazole 95.4%, piperacillin 92.4%, ticarcillin 91.4%, clindamycin 87.8%, cefotetan 81.2%, cefazolin 63.0%, cefuroxime 60.4%, erythromycin 57.8%, penicillin 57.1% and doxycycline 52.1%. beta-lactamases were detected exclusively in Bacteroides spp. isolates (79.1% positive).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2618522     DOI: 10.1080/17843286.1989.11718022

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  2 in total

1.  Fourth Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria.

Authors:  Ingrid Wybo; Dorien Van den Bossche; Oriane Soetens; Evilien Vekens; Kristof Vandoorslaer; Geert Claeys; Youri Glupczynski; Margareta Ieven; Pierrette Melin; Claire Nonhoff; Hector Rodriguez-Villalobos; Jan Verhaegen; Denis Piérard
Journal:  J Antimicrob Chemother       Date:  2013-09-05       Impact factor: 5.790

Review 2.  Role of cephalosporins in the era of Clostridium difficile infection.

Authors:  Mark H Wilcox; James D Chalmers; Carl E Nord; Jane Freeman; Emilio Bouza
Journal:  J Antimicrob Chemother       Date:  2016-09-22       Impact factor: 5.790

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.